Novo's pill keeps winning switchers while the payers behind its volume math walk out

The switch holds in the real world

OCTANE followed 194 patients on the Ro telehealth platform↗ who traded injectable Wegovy or Zepbound for once-daily oral semaglutide and stayed on it ¹. Over three months they lost an average 4.1% of body weight, 8.8 pounds from a 221.6-pound start, and the share clinically obese fell from 87.1% to 65.5% ¹. Oral drugs now account for about a third of US obesity prescriptions, Novo holds more than 80% of new oral scripts, and the pill has passed five million US prescriptions ²³. "Clearly, a lot of patients do even better on the pill than they did on the (injectable) drugs," chief scientific officer Martin Holst Lange said ². The study's limits travel with it: partly self-reported data, a persistence requirement that invites selection bias, results not generalizable ¹.

The payers behind the volume math are walking out

Chief executive Mike Doustdar's case is volume: pills could take half of a market worth $100 billion or more a year by 2030 ². That math runs through subsidized coverage, and for 2027 that channel is thinning. Molina, covering more than 5 million members with over 85% through state Medicaid contracts, cuts its exchange footprint from 14 states to six and filed no 2027 Florida rates↗ ⁴⁵⁶. Alongside CareSource it exits Ohio, stranding roughly 54,000 people ⁶. Cigna leaves all 11 of its marketplace states, about 369,000 members ⁵, one of nine carriers exiting for 2027↗ ⁷. Twelve payers quit Medicare Advantage entirely, Molina staying only through special-needs plans ⁸, with enrollment projected down about two million↗ ⁹.

The retreat has its own price tag

The exits are priced in the payers' books, not the pill's. Enhanced tax credits expired at the end of 2025, and Ohio's average exchange premium jumped from $126 to $233↗ ⁵⁶. Florida's proposed 2027 increases run 3.9% to 39.1% ⁵. Members who do nothing are auto-assigned to the lowest-cost plan at the same metal tier, which may not keep their doctors or their drug formulary ⁷.

Foundayo takes the scripts either way

Lilly's oral Foundayo, approved in April, was tied to 1.5 to 2.4 percentage points more weight loss than the Wegovy pill in an indirect comparison run in Type 2 diabetes↗; no head-to-head trial exists ¹⁰. Whichever plan the stranded land in, an obesity prescription is an obesity prescription, and Foundayo chases all of them. Novo's counter is pipeline: $3.92 billion in potential milestones across two September licensing deals, including a once-weekly oral from Hengrui still in preclinical testing ¹¹, bet by a company down more than 70% from its peak ².

Dated tests, not verdicts

No filing yet connects carrier exits to oral prescription volume; this enrollment season is the first measurement. Medicare shopping opens 15 October ⁹. Molina reports after the close on 21 October↗ ¹². Exchange enrollment opens 1 November, Novo prints nine-month results on 4 November by estimate, unconfirmed by the company↗ ¹³, and 15 December is the deadline for January coverage ⁵. The pill works. Whether anyone still pays for it at scale is what these dates count.